Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.66 – $2.02
Volume120,552
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.56M
Price / earnings
—
Price / book
0.11×
Price / sales
—
EV / sales
—
EV / EBITDA
0.86×
Profitability
Earnings per share
-$20.13
Return on assets
-96.27%
Return on equity
-111.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.77×
Quick ratio
6.77×
Cash ratio
6.47×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.56M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GNPX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.8M
$1.75M
$1.32M
$1.15M
$2.18M
$1.43M
$1.5M
$1.57M
Research and development
$2.68M
$2.75M
$2.2M
$2.19M
$2.5M
$2.54M
$2.84M
$2.76M
Total operating expenses
$4.48M
$4.49M
$3.52M
$3.35M
$4.68M
$3.97M
$4.34M
$4.32M
Operating income
-$4.48M
-$4.49M
-$3.52M
-$3.35M
-$4.68M
-$3.97M
-$4.34M
-$4.32M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.45M
-$4.46M
-$3.79M
-$3.8M
-$4.67M
-$3.96M
-$4.33M
-$4.32M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.45M
-$4.46M
-$3.79M
-$3.8M
-$4.67M
-$3.96M
-$4.33M
-$4.32M
Net income attributable to common shareholders
-$4.45M
-$4.46M
-$3.79M
-$3.8M
-$4.67M
-$3.96M
-$4.33M
-$4.32M
EBITDA
-$4.48M
-$4.49M
-$3.52M
-$3.35M
-$4.68M
-$3.97M
-$4.34M
-$4.32M
Basic earnings per share
-$9.40
-$14.08
-$39.52
-$110.00
-$185.30
-$285.56
-$544.59
-$1,356.30
Diluted earnings per share
-$9.40
-$14.08
-$39.52
-$110.00
-$185.30
-$285.56
-$544.59
-$1,356.30
Recent news
Company coverage with links to the original publishers.
Congressman Tim Moore (R-N.C.), who achieved a 52% return on stock trades in 2025 outperforming the S&P 500, continues buying small-cap stocks in 2026. His latest purchases include additional shares of Genprex, a gene therapy company with a $5.2 million market cap that he also bought in 2025, and Simply Good Foods, which is down 53% over the past 52 weeks. Moore is being closely monitored by investors for his trading activity.
Genprex's research collaborators will present positive preclinical data on the use of Reqorsa® Gene Therapy for treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma at the 2024 EORTC-NCI-AACR Symposium.
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from Benzinga Pro.
United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer.
United Natural Foods shares dipped 15.2% to $12.61 on Wednesday.
Here are some other stocks moving in today's mid-day session.
Gainers
Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line.
Aptorum Group Limited (NASDAQ: APM) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business.
NKGen Biotech, Inc. (NASDAQ: NKGN) gained 46.5% to $1.35.
TRxADE HEALTH, Inc. (NASDAQ: MEDS) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share.
Airship AI Holdings, Inc. (NASDAQ: AISP) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.
Enviva Inc. (NYSE: EVA) rose 33% to $0.9854 after gaining 42% on Tuesday.
American Public Education, Inc. (NASDAQ: APEI) gained 31.8% to $14.99 following upbeat quarterly results.
Dada Nexus Limited (NASDAQ: DADA) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements.
Cemtrex, Inc. (NASDAQ: CETX) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature.
Wave Life Sciences Ltd. (NYSE: WVE) gained 28.5% to $6.16 following upbeat quarterly results.
Vincerx Pharma, Inc. (NASDAQ: VINC) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024.
XORTX Therapeutics Inc. (NASDAQ: XRTX) rose 24.2% to $5.85.
CareMax, Inc. (NASDAQ: CMAX) gained 23.8% to ...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1.5% on Wednesday.
The Dow traded down 0.21% to 38,384.83 while the NASDAQ fell 1.53% to 15,272.34. The S&P 500 also fell, dropping, 1.02% to 4,874.63.
Check This Out: Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
Leading and Lagging Sectors
Real estate shares rose by 0.7% on Wednesday.
In trading on Wednesday, communication services shares fell by 3.3%.
Top Headline
The Federal Reserve maintained interest rates between 5.25% and 5.5% Wednesday during its first meeting of 2024, aligning with market predictions.
Equities Trading UP
Ashland Inc. (NYSE: ASH) shares shot up 17% to $94.34 after the company reported mixed first-quarter financial results and issued guidance.
Shares of Minim, Inc. (NASDAQ: MINM) got a boost, surging 65% to $4.18. David E. Lazar disclosed a 51% active stake in Minim Inc.
Powell Industries, Inc. (NASDAQ: POWL) shares were also up, gaining 48% to $120.92 after the company reported better-than-expected first-quarter financial results and raised its quarterly dividend.
Equities Trading DOWN
Nuvve Holding Corp. (NASDAQ: NVVE) shares dropped 59% to $1.37. Nuvve announced pricing of $9.6 million underwritten public offering of 4.8 million shares ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.